This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | MicrobiomeTrials
← Back to trials NCT05001880
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-03-22Est. Completion: 2026-08-20
Enrollment target: 66 participantsLocations Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States Alliance for Clinical Trials in Oncology, Chicago, Illinois, United States University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States Carle at The Riverfront, Danville, Illinois, United States Carle Physician Group-Effingham, Effingham, Illinois, United States Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States Carle Cancer Center, Urbana, Illinois, United States The Carle Foundation Hospital, Urbana, Illinois, United States University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States Mercy Hospital, Coon Rapids, Minnesota, United States Fairview Southdale Hospital, Edina, Minnesota, United States Unity Hospital, Fridley, Minnesota, United States Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States Mayo Clinic in Rochester, Rochester, Minnesota, United States Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States Other microbiome trials you might be interested in Unresectable Pleural or Peritoneal Malignant Mesothelioma
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal mal…
Scottsdale, United States Est. completion Jan 24, 2016
NSCLC Adenocarcinoma Gastroesophageal Cancer (GC) Gastric Adenocarcinoma Adenocarcinoma of Esophagus Squamous Cell Car. - Esophagus Urothelial Carcinoma (UC) Bladder Cancer
Regions Hospital, Saint Paul, Minnesota, United States
United Hospital, Saint Paul, Minnesota, United States
Rice Memorial Hospital, Willmar, Minnesota, United States
Sanford Cancer Center Worthington, Worthington, Minnesota, United States
Sanford Bismarck Medical Center, Bismarck, North Dakota, United States
Sanford Broadway Medical Center, Fargo, North Dakota, United States
Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States
UT MD Anderson - The Woodlands, Conroe, Texas, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
UT MD Anderson - West Houston, Houston, Texas, United States
UT MD Anderson - League City, League City, Texas, United States
UT MD Anderson - Sugar Land, Sugar Land, Texas, United States
ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States
Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States
Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States
Marshfield Medical Center - Weston, Weston, Wisconsin, United States Mesothelioma
Pleural Mesothelioma
Peritoneal Mesothelioma
Non-Small Cell Lung Cancer NSCLC
Pancreatic Cancer
Biliary Tract Carcinoma
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherap…
Santa Rosa, United States Est. completion Apr 30, 2028